Dr. Nikhil Pande

   MBBS, MD (General Medicine), DM (Medical Oncology)

Book An Appointment

Home / Doctors / Dr. Nikhil Pande

Dr. Nikhil Pande


MBBS, MD (General Medicine), DM (Medical Oncology)


Medical Oncology


HCG NCHRI Cancer Centre - Nagpur


8 Years

  • Dr. Nikhil’s primary interest lies in lung and gastrointestinal malignancies, and he has been part of many clinical research projects.
  • He has excellent communication and presentation skills and has been invited as a speaker in numerous national and international conferences.
  • Dr. Nikhil has handled more than 60000 cases so far.
  • Dr. Nikhil is a member of the European Society of Medical Oncology.
  • He was awarded at the Indian Society of Neuro-Oncology Conference 2017- Best Poster Presentation Award.
  • He was awarded at the Lung Cancer Consortium Asia 2017 – Best Poster Presentation Award.
  • He was awarded at the Lung Cancer Consortium Asia 2017 – Best Trial in Progress Award.
  • Dr. Nikhil has over 25 publications in International Journals and is well-known in academic circles.
    • Simultaneous occurrence of internal capsule infarct and cerebellar haemorrhage in a patient with hemiplegia. BMJ Case Rep. 2014 Jan.  
    • Isolated bilateral upper lobar anomalous pulmonary venous connection–a rare anomaly confirmed on CT imaging. BMJ Case Rep. 2012 May. 
    • Second-Line Palliative Chemotherapy in Advanced Gallbladder Cancer, CAP-IRI: Safe and Effective Option. J Gastrointest Cancer. 2016 May 23.
    • Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumours: feasible and efficacious. Gastrointest Oncol. 2016 Aug;7(4):638-43. 
    • Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer. Does exon 19 deletion differ from exon 21 mutation? –  24February 2018
    • Radiation-Induced -Neuropsychiatric manifestation in a Patient with Brain Metastasis; A Diagnostic & Therapeutic challenge for Consultation – Liaison Psychiatrist. – 25 September 2021
    • Distress Management in Patients with Head & Neck Cancer Before start of Palliative Chemotherapy – A practical approach. – 4 September 2021.
    • Resection of Isolated Port site Metastasis in Gall bladder Cancers - careful selection and Perioperative systemic therapy may improve outcome. 9 September 2018.
    • Impact of exon 19 versus exon 21 EGFR – activating mutation in outcomes with upfront pemetrexed – carboplatin chemotherapy. – 24 October 2017
    • Randomised phase 3 open label study of quality of life of Patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non-EGFR mutated non-small cell lung cancer. – 29 October 2019.

   Practices at

Other Doctors

HCG Call Icon